Skip to main content
SpringerLink
Log in

Interleukin 10

  • Conference paper
New Cytokines as Potential Drugs

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

Interleukin 10 (IL-10) is an anti-inflammatory/immunosuppressive cytokine that inhibits a variety of T cell and monocyte/macrophage cell functions. Discovered as a product of mouse type 2 helper (Th2) T cell lines, IL-10 was initially given the name cytokine synthesis inhibitory factor (CSIF) because of its ability to inhibit cytokine production by mouse type 1 helper T cell (Thl) lines [1]. Subsequent studies showed IL-10 to be a product of several different cell types and to have multiple biological effects like other cytokines [2-9]. The gene encoding mouse IL-10 (mlL-10) was cloned in 1990 [10] and an homologous gene was cloned from a library of a human CD4+ T cell clone in 1991 [11]. Mouse IL-10 and human IL-10 (hIL-10) are similar in size (18.4 and 18.5 kDa respectively) and exist in solution as homod-imers. There is 81% homology between mIL-10 and hIL-10 at the nucleotide level and approximately 73% homology in their amino acid sequence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fiorentino DF, Bond M, Mosmann TR (1989) Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med 170: 2081–2095

    Article  PubMed  CAS  Google Scholar 

  2. Moore KW, O’Garra A, de Waal Malefyt R et al (1993) Interleukin-10. Ann Rev Immunol 11: 165–190

    Article  CAS  Google Scholar 

  3. Howard M, O’Garra A, Ishida H et al (1992) Biological properties of interleukin-10. J Clin Immunol 12: 239–247

    Article  PubMed  CAS  Google Scholar 

  4. Spits H, de Waal Malefyt R (1992) Functional characterization of human IL-10. Internat Arch Allergy Immunol 99: 8–15

    Article  CAS  Google Scholar 

  5. O’Garra A, Stapleton G, Dhar V et al (1990) Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin-10. Internat Immunol 2: 821–832

    Google Scholar 

  6. Thompson-Snipes L, Dhar V, Bond MW et al (1991) Interleukin-10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 173: 507–510

    Article  PubMed  CAS  Google Scholar 

  7. Fiorentino DF, Zlotnik A, Mossmann TR et al (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815–3822

    PubMed  CAS  Google Scholar 

  8. Enk AH, Katz SI (1992) Identification and induction of keratinocyte-derived IL-10. J Immunol 149: 92–95

    PubMed  CAS  Google Scholar 

  9. O’Garra A, Chang R, Go N et al (1992) Ly-1 B (B-l) cells are the main source of B cell-derived interleukin-10. Eur J Immunol 22: 711–717

    Google Scholar 

  10. Moore KV, Vieira P, Fiorentino DF et al (1990) Homology of cytokine synthesis inhibitor factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248: 1230–1234

    Article  PubMed  CAS  Google Scholar 

  11. Vieira P, de Waal-Malefyt R, Dang MN et al (1990) Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 88: 1172–1176

    Article  Google Scholar 

  12. Hsu DH, de Waal Malefyt R, Fiorentino DF et al (1990) Expression of interleukin-10 activity by Epstein-Barr virus protein BCFR I. Science 250: 830–832

    Article  PubMed  CAS  Google Scholar 

  13. Interleukin-10 inhibits cytokine production in vitro and in vivo and protects mice from lethal endotoxemia. Data on file at Schering-Plough Research Institute as P-5769 (December 1992)

    Google Scholar 

  14. Smith SR, Terminelli C, Kenworthy-Bott L et al (1994) The cooperative effects of TNF-a and IFN-γ are determining factors in the ability of IL-10 to protect mice from lethal endotoxemia. J Leukoc Biol 55: 711–718

    PubMed  CAS  Google Scholar 

  15. Pennline KJ, Roque-Gaffney E, Monahan M (1994) Recombinant IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 71: 169–175

    Article  PubMed  CAS  Google Scholar 

  16. Smith SR, Terminell C, Pennline KJ et al (1995) Inhibitory effects of recombinant human Interleukin 10 on disease manifestations in a P-> Fl model of acute graft versus host disease. Transplantation 59: 890–896

    PubMed  CAS  Google Scholar 

  17. Sch 52000: Cross-reactivity of human IL-10 with mouse, rat and monkey. Data on file at Schering-Plough Research Institute as the final report for study D28071 (August 1997)

    Google Scholar 

  18. A preclinical evaluation of SCH 52000 in sublethal endotoxemia and lethal Papio septic shock. Data on file at Schering-Plough Research Institute as D26608 (November 1992)

    Google Scholar 

  19. SCH 52000: Effect of intravenously administered SCH 52000 on response to lipopoly-saccharide in healthy volunteers. Data on file at Schering-Plough Research Institute as the final study report for study C93-163-01 (February 1996)

    Google Scholar 

  20. SCH 52000: Effect of timing on intravenously administered SCH 52000 on response to lipopolysaccharide in healthy male volunteers. Data on file at Schering-Plough Research Institute as the final study report for Study 195-065-01

    Google Scholar 

  21. SCH 52000: Rising single-dose safety and tolerance of SCH 52000: in healthy male volunteers. Data on file at Schering-Plough Research Institute as the final report for study C93-034 (July 1994)

    Google Scholar 

  22. SCH 52000: Effect of intravenously administered SCH 52000 on parameters of immune function in healthy male volunteers. Data on file at Schering-Plough Research Institute as the final report for study C93-055-01 (April 1995)

    Google Scholar 

  23. SCH 52000: Safety, tolerance and effect of subcutaneous administration of SCH 52000 on parameters of immune function in healthy volunteers. Data on file at Schering-Plough Research Institute as the final report for study C93-119 (April 1995)

    Google Scholar 

  24. SCH 52000: Effect of intravenously administered SCH 52000 on response to lipopolysaccharide in healthy volunteers. Data on file at Schering-Plough Research Institute as the final report for study C93-163-01 (February 1996)

    Google Scholar 

  25. Chernoff AE, Granowitz EV, Shapiro L et al (1995) A randomized controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492–5499

    PubMed  CAS  Google Scholar 

  26. Fuchs AC, Granowitz EV, Shapiro L et al (1996) Clinical hematologie and immunolo-gie effects of interleukin-10 in humans. J Clin Immunol 16: 291–303

    Article  PubMed  CAS  Google Scholar 

  27. Yssel H, de Waal Malefyt R, Roncorolo M-G et al (1992) Interleukin 10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol 149: 2378–2384

    PubMed  CAS  Google Scholar 

  28. de Waal Malefyt R, Abrams J, Bennett B et al (1991) IL-10 inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209–1220

    Article  PubMed  Google Scholar 

  29. Fiorentino DF, Zlotnik A, Vieira P et al (1991) IL-10 acts on the antigen presenting cell to inhibit cytokine production by Thl cells. J Immunol 146: 3444–3451

    PubMed  CAS  Google Scholar 

  30. de Waal Malefyt R, Haanen J, Spits H et al (1991) IL-10 and viral 11-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-pressenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med 174: 915–924

    Article  PubMed  Google Scholar 

  31. Spits H, de Waal Malefyt R (1992) Functional characterization of human IL-10. Internat Arch Allergy Immunol 99: 8–15

    Article  CAS  Google Scholar 

  32. Rousset F, Garcia E, DeFrance T et al (1992) Interleukin-10 is a potent growth and differentiation factor for activated human B cells. Proc Natl Acad Sci USA 89: 1890–1893

    Article  PubMed  CAS  Google Scholar 

  33. Briere F, Servet-Delprat C, Bridon J-M et al (1994) Human Interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgGl and IgG3. J Exp Med 179: 757–762

    Article  PubMed  CAS  Google Scholar 

  34. Howard M, Muchamuel T, Andrade S, Menon S. et al (1993) Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177: 1205–1208

    Article  PubMed  CAS  Google Scholar 

  35. Gerard C, Bruyns C, Marchant A et al (1993) IL-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177: 547–550

    Article  PubMed  CAS  Google Scholar 

  36. Bazzoni F, Cassatella MA, Rossi F et al (1991) Phagocytosing neutrophils produce and release high amounts of the neutrophil activating peptide 1/Interleukin 8. J Exp Med 173: 771–774

    Article  PubMed  CAS  Google Scholar 

  37. Bazzoni F, Cassatella MA, Laudonna C et al (1991) Phagocytosis of opsonized yeast induces TNF-alpha mRNA and acccumulation and protein release by human polymor-phonuclear leukocytes. J Leuk Biol 50: 223–228

    CAS  Google Scholar 

  38. Cassatella MA, Guasparri I, Ceska M et al (1993) Interferon-gamma inhibits inter-leukin-8 production by human polymorphonuclear leukocytes. Immunol 78: 177–184

    CAS  Google Scholar 

  39. Cassatella MA, Meda L, Bonora S et al (1993) Interleukin 10 (IL-10) inhibited the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-10 in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178: 2207–2211

    Article  PubMed  CAS  Google Scholar 

  40. Jenkins JK, Malyak M, Arend WP (1994) The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-lp production in human monocytes and neutrophils. Lymphokine and Cytokine Res 13: 47–54

    CAS  Google Scholar 

  41. Hodgson HJ (1995) Inflammatory cytokines, naturally occurring regulators of inflammation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 7: 1021–1023

    Article  PubMed  CAS  Google Scholar 

  42. Braegger CP, MacDonald TT (1994) Immune mechanisms in chronic inflammatory bowel disease. Ann Allergy 72: 135–141

    PubMed  CAS  Google Scholar 

  43. Ligumski M, Simon PL, Karmeli F, Racmilewitz D (1990) Role of Interleukin 1 in inflammatory bowel disease: Enhanced production during active disease. Gut 31: 686–689

    Article  Google Scholar 

  44. Brynskov J, Tvede N, Vilien M et al (1992) Increased concentrations of Interleukin lb, Interleukin-2 and interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 3: 55–58

    Article  Google Scholar 

  45. Brynskov J, Nielsen OH, Ahnfelt-Rnne I, Bendtzen K (1994) Cytokines (immuno-inflammatory hormones and their natural regulation in inflammatory bowel disease (Crohn’s disease and ulcerative colitis): a review. Dig Dis 12: 290–304

    Article  PubMed  CAS  Google Scholar 

  46. Mitsuyama K, Sata M, Tanikawa K et al (1991) Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jap 26: 20–28

    CAS  Google Scholar 

  47. Lobo A, Evans S, Jones SC et al (1991) Plasma interleukin-6 in inflammatory bowel disease. Eur J Gastroenterol and Hepatol 4: 367–372

    Google Scholar 

  48. MacDonald TT, Hutchings P, Choy MY et al (1990) Tumor necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81: 301–305

    Article  PubMed  CAS  Google Scholar 

  49. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1995) Distribution and density of TNF immunoreactivity in chronic inflammatory bowel disease. Adv Exp Med Biol 371B: 1327–1330

    PubMed  CAS  Google Scholar 

  50. Stevens C, Walz G, Singaram C et al (1992) Tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 37: 818–826

    Article  PubMed  CAS  Google Scholar 

  51. Hyams J, Treem W, Eddy E et al (1991) Tumor necrosis factor-a is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 12: 233–236

    Article  PubMed  CAS  Google Scholar 

  52. Stokkers PCF, Camoglio L, Van Deventer SJH (1996) Tumor necrosis factor (TNF) in inflammatory bowel disease: Gene polymorphisms, animal models and potential for anti-TNF therapy. J Inflamm 47: 97–103

    CAS  Google Scholar 

  53. Duchman R, Kaiser I, Hermann E et al (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102: 448–455

    Article  Google Scholar 

  54. Kuhn R, Lohier J, Rennick D et al (1993) Interleukin-10 deficient mice develop chronic enterocolitis. Cell 75: 263–274

    Article  PubMed  CAS  Google Scholar 

  55. Berg DJ, Davidson N, Kuhn R et al (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ THl-like responses. J Clin Invest 98: 1010–1020

    Article  PubMed  CAS  Google Scholar 

  56. Powrie F, Leach MW, Mauze S et al (1994) Inhibition of Thl responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45 RB high CD-4+ T cells. Immunity 1: 553–562

    Article  PubMed  CAS  Google Scholar 

  57. Powrie F, Leach MW, Mauze S, Menon S, Caddie LB, Coffman RL (1994) Inhibition of Thl responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1: 553–562

    Article  PubMed  CAS  Google Scholar 

  58. McCall RD, Haskill S, Zimmerman EM et al (1994) Tissue interleukin-1 and inteleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterol 10: 960–972

    Google Scholar 

  59. Herforth HH, Mohanty SP, Rath HC et al (1996) Interleukin 10 suppresses experimental chronic granulomatous inflammation induced by bacterial cell wall polymers. Gut 39: 836–845

    Article  Google Scholar 

  60. Powrie F (1995) T cells in inflammatory bowel disease: Protective and pathogenic rolls. Immunity 3: 171–174

    Article  PubMed  CAS  Google Scholar 

  61. Kucharzik T, Stoll R, Lugering N et al (1995) Circulating anti-inflammatory cytokine IL-10 patients with inflammatory bowel disease (IBD). Clin Exp Immunol 100: 452–456

    Article  PubMed  CAS  Google Scholar 

  62. Mullin GE, Vezza FR, Sampat A et al (1993) Abnormal mRNA production in the intestinal mucosal lesions of inflammatory bowel disease [abstract]. Gastroenterol 104: A751

    Google Scholar 

  63. Niessner M, Volk BA (1995) Altered Thl/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101: 428–435

    Article  PubMed  CAS  Google Scholar 

  64. Nielsen OH, Koppen T, Rudiger N et al (1996) Involvement of interleukin-4 and-10 in inflammatory bowel disease. Dig Dis Sci 41: 1786–1793

    Article  PubMed  CAS  Google Scholar 

  65. Radford-Smith G, Jewell DP (1996) Cytokines and inflammatory bowel disease. Bail-lieres Clin Gastroenterol 10: 151–164

    CAS  Google Scholar 

  66. Peppercorn MA (1992) Advances in drug therapy for inflammatory bowel disease. Ann Rev Med 43: 125–135

    Article  Google Scholar 

  67. Hanauer SB (1993) Medical therapy of ulcerative colitis. Lancet 342: 412–417

    Article  PubMed  CAS  Google Scholar 

  68. Hanauer SB (1996) Inflammatory bowel disease. New Engl J Med 334: 841–848

    Article  PubMed  CAS  Google Scholar 

  69. Present DH, Korelitz BL, Wisch N et al (1980) Treatment of Crohn’s disease with 6-mercaptopurine. New Engl J Med 302: 981–987

    Article  PubMed  CAS  Google Scholar 

  70. Sandborn WJ (1996) A review of immune modifier therapy for inflammatory bowel disease: Azathioprine 6-Mercaptopurine, cyclosporine and methotrexate. Am J Gastroen-terol 91: 423–433

    CAS  Google Scholar 

  71. O’Donoghue DP, Dawson AM, Powell-Tuck J et al (1978) Double blind withdrawal trial of azathioprine as maintenance treatment for CD. Lancet 2: 955–957

    Article  PubMed  Google Scholar 

  72. Hawthorn AB, Logan RFA, Hawkey CJ et al (1992) Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305: 20–22

    Article  Google Scholar 

  73. Choi PM, Targan SR (1994) Innunomodulator therapy in inflammatory bowel disease. Dig DisSci 39: 1885–1892

    Article  CAS  Google Scholar 

  74. Lichtiger S, Present DH, Kornbluth AA et al (1994) Cyclosporine in severe ulcerative colitis refractor to steriod therapy. New Engl J Med 330: 1841–1845

    Article  CAS  Google Scholar 

  75. Brynskov J, Freund L, Rasmussen SN (1989) A placebo controlled double-blind randomized trial of cyclosporin therapy in active Crohn’s disease. New Engl J Med 321: 845–850

    Article  PubMed  CAS  Google Scholar 

  76. Sandborn WJ (1995) A critical review of cyclosporin therapy in inflammatory bowel disease. Infamm Bowel Dis 1: 48–63

    Article  Google Scholar 

  77. Baron TH, Truss CD, Elson CO (1993) Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 38: 1851–1856

    Article  PubMed  CAS  Google Scholar 

  78. Feagan BG, Rochon J, Fedorak RN et al (1995) Methotrexate for the treatment of Crohn’s disease. New Engl J Med 332: 292–297

    Article  PubMed  CAS  Google Scholar 

  79. Summers RW, Switz DM, Sessions JT Jr et al (1979) National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterol 77: 847–869

    CAS  Google Scholar 

  80. Malchow H, Ewe K, Bandes JW et al (1984) European Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterol 86: 249–266

    CAS  Google Scholar 

  81. Lew W, Oppenheim JJ, Matsushima K (1988) Analysis of the suppression of IL-loc and IL-1(3 production in human peripheral blood mononuclear adherent cells by a gluco-corticoid hormone. J Immunol 140: 1895–1902

    PubMed  CAS  Google Scholar 

  82. Ayra SK, Wong-Staal F, Gallo RC (1984) Dexamethasone-mediated inhibition of human T cell growth factor and gamma interferon messenger RNA. J Immunol 133: 273–276

    Google Scholar 

  83. Singleton JW, Law H, Kelly ML Jr et al (1979) National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterol 77: 870–872

    CAS  Google Scholar 

  84. Ruttgers P, Lofberg R, Malchow H et al (1994) A comparison of budesonide with pred-nisolone for active Crohn’s disease. New Eng J Med 331: 842–845

    Article  Google Scholar 

  85. Greenberg GR, Feagan BG, Martin F et al (1994) Oral budesonide for active Crohn’s disease. New Eng J Med 331: 836–841

    Article  PubMed  CAS  Google Scholar 

  86. Van Dellumen HM, Van De Venter SJH, Hommes DW, Meenan J et al (1995) Treatment of Crohn’s disease with anti-TNF chimeric monoclonal antibody (cA2). Gastroenterol 109: 129–135

    Article  Google Scholar 

  87. McCabe RP, Wood J, Van Deventer et al (1996) A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease [abstract], Gastroenterol 110: A962

    Google Scholar 

  88. Sands BE, Podolsky DK, Tremaine WJ et al (1996) Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe steroid-refractory ulcerative colitis (UC) [abstract]. Gastroenterol 110: A1008

    Article  Google Scholar 

  89. Evans RC, Clark L, Heath P (1996) Treatment of ulcerative colitis with an engineered human anti-TNF-a antibody CDP 571 [abstract]. Gastroenterol 110: A905

    Article  Google Scholar 

  90. Schreiber S, Heinig T, Thiele H-G, Readier A (1995) Immunoregulatory role of inter-leukin 10 in patients with inflammatory bowel disease. Gastroenterol 108: 1434–1444

    Article  CAS  Google Scholar 

  91. Chernoff AE, Granowitz EV, Shapiro L et al (1995) A randomized controlled trial of IL-10 in humans’ inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492–5499

    PubMed  CAS  Google Scholar 

  92. Pajkrt D, Camoglio L, Monique CM (1997) Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia. J Immunol 158: 3971–3977

    PubMed  CAS  Google Scholar 

  93. SCH 52000: Rising single-dose, safety and tolerance of Sch 52000 administered sub-cutaneously to healthy female volunteers. Data on file at Schering-Plough Research Institute as the final report for study C94-094-01 (November 1995)

    Google Scholar 

  94. Van Deventer SJH, Elson CO, Fedorak RN et al (1996) Safety, tolerance, pharmacoki-netics and pharmacodynamics of recombinant interleukin-10 (Sch 52000) in patients with steroid-refractory Crohn’s disease [abstract]. Gastroenterol 110: A1034

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ, 07033, USA

    Satwant Narula & Sidney Smith

  2. Canji Inc., San Diego, CA, 92121, USA

    Paul Grint

Authors
  1. Satwant Narula
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sidney Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Grint
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ, 07033, USA

    Satwant K. Narula

  2. DNAX Research Institute, 901 California Avenue, Palo Alto, CA, 94304, USA

    Robert Coffman

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this paper

Cite this paper

Narula, S., Smith, S., Grint, P. (2000). Interleukin 10. In: Narula, S.K., Coffman, R. (eds) New Cytokines as Potential Drugs. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8456-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8456-3_2

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9575-0

  • Online ISBN: 978-3-0348-8456-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation